{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:34:17Z","timestamp":1794008057125,"version":"4.8.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T00:00:00Z","timestamp":1719705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicine in Drug Discovery"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.medidd.2024.100195","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T13:54:40Z","timestamp":1719842080000},"page":"100195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy"],"prefix":"10.1016","volume":"23","author":[{"given":"Rahul","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghu","family":"Solanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laxminarayan","family":"Rawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Tabasum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranay","family":"Tanwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumitro","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1760-4903","authenticated-orcid":false,"given":"Akash","family":"Sabarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medidd.2024.100195_b0005","doi-asserted-by":"crossref","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002\/ijc.33588. Epub ahead of print. PMID: 33818764.","DOI":"10.1002\/ijc.33588"},{"key":"10.1016\/j.medidd.2024.100195_b0010","doi-asserted-by":"crossref","unstructured":"Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024). Cancer statistics, 2024. CA: a cancer journal for clinicians. 2024 Jan 17. doi:10.3322\/caac.21820.","DOI":"10.3322\/caac.21863"},{"issue":"10","key":"10.1016\/j.medidd.2024.100195_b0015","doi-asserted-by":"crossref","first-page":"e64943","DOI":"10.7554\/eLife.64943","article-title":"A subcellular map of the human kinome","volume":"14","author":"Zhang","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.medidd.2024.100195_b0020","doi-asserted-by":"crossref","unstructured":"Karve TM, Cheema AK. Small changes huge impact: the role of protein posttranslational modifications in cellular homeostasis and disease. J Amino Acids. 2011;2011:207691. doi: 10.4061\/2011\/207691. Epub 2011 Jul 21. PMID: 22312457; PMCID: PMC3268018.","DOI":"10.4061\/2011\/207691"},{"issue":"10","key":"10.1016\/j.medidd.2024.100195_b0025","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cellsig.2011.05.004","article-title":"Akt signalling in health and disease","volume":"23","author":"Hers","year":"2011","journal-title":"Cell Signal"},{"issue":"7","key":"10.1016\/j.medidd.2024.100195_b0030","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.medidd.2024.100195_b0035","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.medidd.2024.100195_b0040","first-page":"989","article-title":"Lipid kinases play crucial and multiple roles in membrane trafficking and signaling","volume":"18","author":"Heath","year":"2003","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.medidd.2024.100195_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharmacol Res"},{"issue":"5600","key":"10.1016\/j.medidd.2024.100195_b0050","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.medidd.2024.100195_b0055","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/prot.21444","article-title":"Classification and functional annotation of eukaryotic protein kinases","volume":"68","author":"Miranda-Saavedra","year":"2007","journal-title":"Proteins"},{"issue":"2","key":"10.1016\/j.medidd.2024.100195_b0060","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-2443.1996.d01-234.x","article-title":"Vertebrate non-receptor protein-tyrosine kinase families","volume":"1","author":"Neet","year":"1996","journal-title":"Genes Cells"},{"issue":"1","key":"10.1016\/j.medidd.2024.100195_b0065","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nrg2707","article-title":"Kinase mutations in human disease: interpreting genotype-phenotype relationships","volume":"11","author":"Lahiry","year":"2010","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.medidd.2024.100195_b0070","doi-asserted-by":"crossref","unstructured":"Hunter T. The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. Philos Trans R Soc Lond B Biol Sci. 1998 Apr 29;353(1368):583-605. doi: 10.1098\/rstb.1998.0228. PMID: 9602534; PMCID: PMC1692245.","DOI":"10.1098\/rstb.1998.0228"},{"key":"10.1016\/j.medidd.2024.100195_b0075","series-title":"Targeting protein kinases for cancer therapy","author":"Matthews","year":"2011"},{"issue":"49","key":"10.1016\/j.medidd.2024.100195_b0080","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1038\/sj.onc.1203957","article-title":"The protein tyrosine kinase family of the human genome","volume":"19","author":"Robinson","year":"2000","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.medidd.2024.100195_b0085","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.medidd.2024.100195_b0090","doi-asserted-by":"crossref","unstructured":"Wu J, Li W, Craddock BP, Foreman KW, Mulvihill MJ, Ji QS, Miller WT, Hubbard SR. Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor. EMBO J. 2008 Jul 23;27(14):1985-94. doi: 10.1038\/emboj.2008.116. Epub 2008 Jun 19. PMID: 18566589; PMCID: PMC2486273.","DOI":"10.1038\/emboj.2008.116"},{"key":"10.1016\/j.medidd.2024.100195_b0095","doi-asserted-by":"crossref","unstructured":"Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011 Mar;75(1):50-83. doi: 10.1128\/MMBR.00031-10. Erratum in: Microbiol Mol Biol Rev. 2012 Jun;76(2):496. PMID: 21372320; PMCID: PMC3063353.","DOI":"10.1128\/MMBR.00031-10"},{"key":"10.1016\/j.medidd.2024.100195_b0100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","article-title":"UALCAN: An update to the integrated cancer data analysis platform","volume":"25","author":"Chandrashekar","year":"2022","journal-title":"Neoplasia"},{"issue":"8","key":"10.1016\/j.medidd.2024.100195_b0105","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","article-title":"UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses","volume":"19","author":"Chandrashekar","year":"2017","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.medidd.2024.100195_b0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.neuron.2006.09.034","article-title":"Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors","volume":"53","author":"Wehrman","year":"2007","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/j.medidd.2024.100195_b0115","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0092-8674(02)00966-2","article-title":"Ligand-induced, receptor-mediated dimerization and activation of EGF receptor","volume":"110","author":"Schlessinger","year":"2002","journal-title":"Cell"},{"issue":"14","key":"10.1016\/j.medidd.2024.100195_b0120","doi-asserted-by":"crossref","first-page":"7732","DOI":"10.1073\/pnas.97.14.7732","article-title":"Crystal structure of human stem cell factor: implication for stem cell factor receptor dimerization and activation","volume":"97","author":"Zhang","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"22","key":"10.1016\/j.medidd.2024.100195_b0125","doi-asserted-by":"crossref","first-page":"15970","DOI":"10.1016\/S0021-9258(19)49629-4","article-title":"Dimerization and activation of the kit receptor by monovalent and bivalent binding of the stem cell factor","volume":"267","author":"Lev","year":"1992","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.medidd.2024.100195_b0130","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M","article-title":"FGFs, heparan sulfate and FGFRs: complex interactions essential for development","volume":"22","author":"Ornitz","year":"2000","journal-title":"Bioessays"},{"key":"10.1016\/j.medidd.2024.100195_b0135","doi-asserted-by":"crossref","unstructured":"Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2001;2(3):REVIEWS3005. doi: 10.1186\/gb-2001-2-3-reviews3005. Epub 2001 Mar 9. PMID: 11276432; PMCID: PMC138918.","DOI":"10.1186\/gb-2001-2-3-reviews3005"},{"key":"10.1016\/j.medidd.2024.100195_b0140","doi-asserted-by":"crossref","unstructured":"Black LE, Longo JF, Carroll SL. Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia. Am J Pathol. 2019 Oct;189(10):1898-1912. doi: 10.1016\/j.ajpath.2019.06.008. Epub 2019 Jul 25. PMID: 31351986; PMCID: PMC6892224.","DOI":"10.1016\/j.ajpath.2019.06.008"},{"key":"10.1016\/j.medidd.2024.100195_b0145","doi-asserted-by":"crossref","unstructured":"Hubbard SR, Miller WT. Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol. 2007 Apr;19(2):117-23. doi: 10.1016\/j.ceb.2007.02.010. Epub 2007 Feb 16. PMID: 17306972; PMCID: PMC2536775.","DOI":"10.1016\/j.ceb.2007.02.010"},{"issue":"9","key":"10.1016\/j.medidd.2024.100195_b0150","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/nrc2900","article-title":"Functional proteomics to dissect tyrosine kinase signalling pathways in cancer","volume":"10","author":"Kolch","year":"2010","journal-title":"Nat Rev Can"},{"issue":"9","key":"10.1016\/j.medidd.2024.100195_b0155","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/bies.20459","article-title":"An intracrine view of angiogenesis","volume":"28","author":"Re","year":"2006","journal-title":"Bioessays"},{"issue":"4","key":"10.1016\/j.medidd.2024.100195_b0160","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbrc.2004.09.171","article-title":"Src protein-tyrosine kinase structure and regulation","volume":"324","author":"Roskoski","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.medidd.2024.100195_b0165","doi-asserted-by":"crossref","unstructured":"Neben CL, Lo M, Jura N, Klein OD. Feedback regulation of RTK signaling in development. Dev Biol. 2019 Mar 1;447(1):71-89. doi: 10.1016\/j.ydbio.2017.10.017. Epub 2017 Oct 26. PMID: 29079424; PMCID: PMC5920792.","DOI":"10.1016\/j.ydbio.2017.10.017"},{"issue":"5","key":"10.1016\/j.medidd.2024.100195_b0170","doi-asserted-by":"crossref","first-page":"13574","DOI":"10.1038\/srep13574","article-title":"EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway","volume":"4","author":"Tsai","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.medidd.2024.100195_b0175","doi-asserted-by":"crossref","unstructured":"Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014;2014:852748. doi: 10.1155\/2014\/852748. Epub 2014 Sep 7. PMID: 25276427; PMCID: PMC4170925.","DOI":"10.1155\/2014\/852748"},{"issue":"9","key":"10.1016\/j.medidd.2024.100195_b0180","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/gm191","article-title":"Detection of DNA fusion junctions for BCR-ABL translocations by Anchored ChromPET","volume":"2","author":"Shibata","year":"2010","journal-title":"Genome Med"},{"issue":"1","key":"10.1016\/j.medidd.2024.100195_b0185","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/s41467-021-21613-6","article-title":"Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting","volume":"12","author":"Du","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.medidd.2024.100195_b0190","doi-asserted-by":"crossref","unstructured":"Schrevel M, Osse EM, Prins FA, Trimbos JBMZ, Fleuren GJ, Gorter A, Jordanova ES. Autocrine expression of the epidermal growth factor receptor ligand heparin-binding EGF-like growth factor in cervical cancer. Int J Oncol. 2017 Jun;50(6):1947-1954. doi: 10.3892\/ijo.2017.3980. Epub 2017 May 3. PMID: 28498437; PMCID: PMC5435322.","DOI":"10.3892\/ijo.2017.3980"},{"issue":"1","key":"10.1016\/j.medidd.2024.100195_b0195","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.medidd.2024.100195_b0200","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.medidd.2024.100195_b0205","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"4","key":"10.1016\/j.medidd.2024.100195_b0210","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1021\/jm901132v","article-title":"Selectively nonselective kinase inhibition: striking the right balance","volume":"53","author":"Morphy","year":"2010","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.medidd.2024.100195_b0215","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.taap.2009.12.032","article-title":"The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity","volume":"244","author":"Hasinoff","year":"2010","journal-title":"Toxicol Appl Pharmacol"},{"issue":"24","key":"10.1016\/j.medidd.2024.100195_b0220","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.1021\/jm8010299","article-title":"Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states","volume":"51","author":"Kufareva","year":"2008","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.medidd.2024.100195_b0225","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/cb500129t","article-title":"Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?","volume":"9","author":"Zhao","year":"2014","journal-title":"ACS Chem Biol"},{"issue":"20","key":"10.1016\/j.medidd.2024.100195_b0230","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.2174\/138161212800672813","article-title":"New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors","volume":"18","author":"Lamba","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.medidd.2024.100195_b0235","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1039\/C2MD20180A","article-title":"Approaches to discover non-ATP site kinase inhibitors","volume":"4","author":"Gavrin","year":"2013","journal-title":"MedChemComm"},{"issue":"5","key":"10.1016\/j.medidd.2024.100195_b0240","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1021\/jm101396q","article-title":"Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors","volume":"54","author":"Leproult","year":"2011","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.medidd.2024.100195_b0245","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chembiol.2012.12.006","article-title":"Developing irreversible inhibitors of the protein kinase cysteinome","volume":"20","author":"Liu","year":"2013","journal-title":"Chem Biol"},{"issue":"4","key":"10.1016\/j.medidd.2024.100195_b0250","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ccr.2013.02.019","article-title":"Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties","volume":"23","author":"Bono","year":"2013","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.medidd.2024.100195_b0255","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"19","key":"10.1016\/j.medidd.2024.100195_b0260","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.3390\/cancers13194820","article-title":"Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance","volume":"13","author":"Alves","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5531","key":"10.1016\/j.medidd.2024.100195_b0265","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.medidd.2024.100195_b0270","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/13543784.2011.546344","article-title":"Mechanisms of drug resistance in kinases","volume":"20","author":"Barouch-Bentov","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.medidd.2024.100195_b0275","doi-asserted-by":"crossref","unstructured":"Itonaga H, Tsushima H, Hata T, Matsuo E, Imanishi D, Imaizumi Y, Kawaguchi Y, Fukushima T, Doi Y, Mori S, Kamihira S, Tomonaga M, Miyazaki Y. Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa. Int J Hematol. 2012 Feb;95(2):209-13. doi: 10.1007\/s12185-012-1005-1. Epub 2012 Jan 20. PMID: 22262141.","DOI":"10.1007\/s12185-012-1005-1"},{"issue":"2","key":"10.1016\/j.medidd.2024.100195_b0280","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.3747\/co.v18i2.391","article-title":"Monitoring response and resistance to treatment in chronic myeloid leukemia","volume":"18","author":"Assouline","year":"2011","journal-title":"Curr Oncol"},{"key":"10.1016\/j.medidd.2024.100195_b0285","article-title":"circ_0080145 enhances imatinib resistance of chronic myeloid leukemia by regulating miR-326\/PPFIA1 Axis","author":"Che","year":"2020","journal-title":"Cancer Biother Radiopharm"},{"issue":"243","key":"10.1016\/j.medidd.2024.100195_b0290","article-title":"Circ_0009910 promotes imatinib resistance through ULK1-induced autophagy by sponging miR-34a-5p in chronic myeloid leukemia","volume":"15","author":"Cao","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.medidd.2024.100195_b0295","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, Krahnke T, Cortes J, Druker BJ; International Randomized Study of Interferon and STI571 (IRIS) Investigators. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer. 2009 Feb 1;115(3):551-60. doi: 10.1002\/cncr.24066. Erratum in: Cancer. 2010 Aug 1;116(15):3750. Santini, Valeria [added]. PMID: 19117345; PMCID: PMC4445370.","DOI":"10.1002\/cncr.24066"},{"issue":"1","key":"10.1016\/j.medidd.2024.100195_b0300","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","article-title":"Third-line therapy for chronic myeloid leukemia: current status and future directions","volume":"14","author":"Cortes","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.medidd.2024.100195_b0305","doi-asserted-by":"crossref","unstructured":"Cortes JE, Jiang Q, Wang J, Weng J, Zhu H, Liu X, Hochhaus A, Kim DW, Radich J, Savona M, Martin-Regueira P, Sy O, Gurnani R, Saglio G. Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. Leukemia. 2020 Aug;34(8):2064-2073. doi: 10.1038\/s41375-020-0805-1. Epub 2020 Apr 7. PMID: 32265500; PMCID: PMC7387297.","DOI":"10.1038\/s41375-020-0805-1"},{"key":"10.1016\/j.medidd.2024.100195_b0310","article-title":"Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa","volume":"95(2):209-13","author":"Itonaga","year":"2012","journal-title":"Int J Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.medidd.2024.100195_b0315","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/j.clml.2011.03.032","article-title":"Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation","volume":"11","author":"Cornelison","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.medidd.2024.100195_b0320","doi-asserted-by":"crossref","unstructured":"Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE, Kantarjian H; Omacetaxine 202 Study Group. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012 Sep 27;120(13):2573-80. doi: 10.1182\/blood-2012-03-415307. Epub 2012 Aug 15. PMID: 22896000; PMCID: PMC4916583.","DOI":"10.1182\/blood-2012-03-415307"},{"issue":"2","key":"10.1016\/j.medidd.2024.100195_b0325","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/oncolo\/oyab040","article-title":"FDA approval summary: revised indication and dosing regimen for ponatinib based on the results of the OPTIC trial","volume":"27","author":"Pulte","year":"2022","journal-title":"Oncologist"},{"issue":"24","key":"10.1016\/j.medidd.2024.100195_b0330","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.medidd.2024.100195_b0335","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood.2021014689","article-title":"Asciminib: a new therapeutic option in chronic-phase CML with treatment failure","volume":"139","author":"Yeung","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.medidd.2024.100195_b0340","doi-asserted-by":"crossref","unstructured":"Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005 Mar;2(3):e73. doi: 10.1371\/journal.pmed.0020073. Epub 2005 Feb 22. PMID: 15737014; PMCID: PMC549606.","DOI":"10.1371\/journal.pmed.0020073"},{"issue":"4","key":"10.1016\/j.medidd.2024.100195_b0345","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3816\/CLC.2009.n.039","article-title":"Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway","volume":"10","author":"Nguyen","year":"2009","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.medidd.2024.100195_b0350","doi-asserted-by":"crossref","unstructured":"Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5. doi: 10.1073\/pnas.0709662105. Epub 2008 Jan 28. PMID: 18227510; PMCID: PMC2538882.","DOI":"10.1073\/pnas.0709662105"},{"key":"10.1016\/j.medidd.2024.100195_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2022.105787","article-title":"Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R\/T790M, and L858R\/T790M\/C797S forms of EGFR","volume":"147","author":"Todsaporn","year":"2022","journal-title":"Comput Biol Med"},{"issue":"1","key":"10.1016\/j.medidd.2024.100195_b0360","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40880-019-0414-4","article-title":"The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)","volume":"39","author":"Zhang","year":"2019","journal-title":"Cancer Commun (Lond)"},{"issue":"9","key":"10.1016\/j.medidd.2024.100195_b0365","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jtho.2021.05.006","article-title":"Apatinib plus gefitinib as first-line treatment in advanced EGFR-mut$ant NSCLC: the phase III ACTIVE study (CTONG1706)","volume":"16","author":"Zhao","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.medidd.2024.100195_b0370","doi-asserted-by":"crossref","first-page":"e000060","DOI":"10.1136\/esmoopen-2016-000060","article-title":"Mechanisms of resistance to EGFR-targeted drugs: lung cancer","volume":"1","author":"Morgillo","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.medidd.2024.100195_b0375","doi-asserted-by":"crossref","unstructured":"Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158\/2159-8290.CD-14-0337. Epub 2014 Jun 3. PMID: 24893891; PMCID: PMC4315625.","DOI":"10.1158\/2159-8290.CD-14-0337"},{"key":"10.1016\/j.medidd.2024.100195_b0380","doi-asserted-by":"crossref","unstructured":"Scott LJ. Osimertinib as first-line therapy in advanced NSCLC: a profile of its use. Drugs Ther Perspect. 2018;34(8):351-357. doi: 10.1007\/s40267-018-0536-9. Epub 2018 Jul 6. Erratum in: Drugs Ther Perspect. 2019;35(1):50. PMID: 30631243; PMCID: PMC6300577.","DOI":"10.1007\/s40267-018-0536-9"},{"key":"10.1016\/j.medidd.2024.100195_b0385","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2021.09.041","article-title":"Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT)","volume":"159","author":"Sakata","year":"2021","journal-title":"Eur J Can"},{"key":"10.1016\/j.medidd.2024.100195_b0390","doi-asserted-by":"crossref","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019 Oct;121(9):725-737. doi: 10.1038\/s41416-019-0573-8. Epub 2019 Sep 30. PMID: 31564718; PMCID: PMC6889286.","DOI":"10.1038\/s41416-019-0573-8"},{"key":"10.1016\/j.medidd.2024.100195_b0395","doi-asserted-by":"crossref","unstructured":"Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056\/NEJMoa1612674. Epub 2016 Dec 6. PMID: 27959700; PMCID: PMC6762027.","DOI":"10.1056\/NEJMoa1612674"},{"key":"10.1016\/j.medidd.2024.100195_b0400","doi-asserted-by":"crossref","unstructured":"Tsuboi M, Herbst RS, John T, Kato T, Majem M, Groh\u00e9 C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056\/NEJMoa2304594. Epub 2023 Jun 4. PMID: 37272535.","DOI":"10.1056\/NEJMoa2304594"},{"key":"10.1016\/j.medidd.2024.100195_b0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2018.01.015","article-title":"Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib","volume":"118","author":"Liu","year":"2018","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.medidd.2024.100195_b0410","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.21037\/jtd.2019.08.30","article-title":"Mechanisms of resistance to osimertinib","volume":"12","author":"Lazzari","year":"2020","journal-title":"J Thorac Dis"},{"issue":"2","key":"10.1016\/j.medidd.2024.100195_b0415","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1158\/1541-7786.MCR-18-0628","article-title":"Activation of AXL as a preclinical acquired resistance mechanism against osimertinib treatment in EGFR-mutant non-small cell lung cancer cells","volume":"17","author":"Namba","year":"2019","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.medidd.2024.100195_b0420","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/GO.21.00067","article-title":"Real-world data on the prevalence of anaplastic lymphoma kinase-positive non-small-cell lung cancer in the middle east and North Africa","volume":"7","author":"Jazieh","year":"2021","journal-title":"JCO Glob Oncol"},{"issue":"6","key":"10.1016\/j.medidd.2024.100195_b0425","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/CLEP.S69718","article-title":"Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors","volume":"20","author":"Chia","year":"2014","journal-title":"Clin Epidemiol"},{"issue":"7153","key":"10.1016\/j.medidd.2024.100195_b0430","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.medidd.2024.100195_b0435","doi-asserted-by":"crossref","unstructured":"Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, Drew L, Saeh JC, Crosby K, Sequist LV, Iafrate AJ, Engelman JA. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012 Feb 8;4(120):120ra17. doi: 10.1126\/scitranslmed.3003316. Epub 2012 Jan 25. PMID: 22277784; PMCID: PMC3385512.","DOI":"10.1126\/scitranslmed.3003316"},{"key":"10.1016\/j.medidd.2024.100195_b0440","doi-asserted-by":"crossref","unstructured":"Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, Pferdekamper AC, Li J, Kasibhatla S, Sun F, Sun X, Hua S, McNamara P, Mahmood S, Lockerman EL, Fujita N, Nishio M, Harris JL, Shaw AT, Engelman JA. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014 Jun;4(6):662-673. doi: 10.1158\/2159-8290.CD-13-0846. Epub 2014 Mar 27. PMID: 24675041; PMCID: PMC4068971.","DOI":"10.1158\/2159-8290.CD-13-0846"},{"key":"10.1016\/j.medidd.2024.100195_b0445","doi-asserted-by":"crossref","unstructured":"Katayama R, Friboulet L, Koike S, Lockerman EL, Khan TM, Gainor JF, Iafrate AJ, Takeuchi K, Taiji M, Okuno Y, Fujita N, Engelman JA, Shaw AT. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res. 2014 Nov 15;20(22):5686-96. doi: 10.1158\/1078-0432.CCR-14-1511. Epub 2014 Sep 16. PMID: 25228534; PMCID: PMC4233168..","DOI":"10.1158\/1078-0432.CCR-14-1511"},{"issue":"3","key":"10.1016\/j.medidd.2024.100195_b0450","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.neo.2016.02.001","article-title":"Elucidation of resistance mechanisms to second-generation ALK inhibitors alectinib and ceritinib in non-small cell lung cancer cells","volume":"18","author":"Dong","year":"2016","journal-title":"Neoplasia"},{"issue":"3","key":"10.1016\/j.medidd.2024.100195_b0455","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/cancers10030062","article-title":"Tumor resistance against ALK targeted therapy-where it comes from and where it goes","volume":"10","author":"Sharma","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.medidd.2024.100195_b0460","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/1574884711666160502124134","article-title":"Resistance to crizotinib in advanced non-small cell lung cancer (NSCLC) with ALK rearrangement: mechanisms, treatment strategies and new targeted therapies","volume":"11","author":"Casaluce","year":"2016","journal-title":"Curr Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.medidd.2024.100195_b0465","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.2147\/DDDT.S113500","article-title":"Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy","volume":"5","author":"Santarpia","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.medidd.2024.100195_b0470","doi-asserted-by":"crossref","unstructured":"Dardaei L, Wang HQ, Singh M, Fordjour P, Shaw KX, Yoda S, Kerr G, Yu K, Liang J, Cao Y, Chen Y, Lawrence MS, Langenbucher A, Gainor JF, Friboulet L, Dagogo-Jack I, Myers DT, Labrot E, Ruddy D, Parks M, Lee D, DiCecca RH, Moody S, Hao H, Mohseni M, LaMarche M, Williams J, Hoffmaster K, Caponigro G, Shaw AT, Hata AN, Benes CH, Li F, Engelman JA. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Nat Med. 2018 May;24(4):512-517. doi: 10.1038\/nm.4497. Epub 2018 Mar 5. PMID: 29505033; PMCID: PMC6343825.","DOI":"10.1038\/nm.4497"},{"issue":"1","key":"10.1016\/j.medidd.2024.100195_b0475","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/07853890.2023.2187077","article-title":"Effectiveness of ALK inhibitors in treatment of CNS metastases in NSCLC patients","volume":"55","author":"Gil","year":"2023","journal-title":"Ann Med"},{"issue":"21","key":"10.1016\/j.medidd.2024.100195_b0480","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1158\/1078-0432.CCR-16-1293","article-title":"FDA approval: alectinib for the treatment of metastatic, ALK-positive non-small cell lung cancer following crizotinib","volume":"22","author":"Larkins","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.medidd.2024.100195_b0485","doi-asserted-by":"crossref","first-page":"316","DOI":"10.18632\/oncotarget.27875","article-title":"Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach","volume":"12","author":"Carcereny","year":"2021","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.medidd.2024.100195_b0490","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2147\/DDDT.S147499","article-title":"Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy","volume":"8","author":"Ali","year":"2019","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"10.1016\/j.medidd.2024.100195_b0495","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/14656566.2022.2161880","article-title":"An update on lorlatinib: a novel first line treatment for ALK-positive advanced lung cancer","volume":"24","author":"Riudavets","year":"2023","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.medidd.2024.100195_b0500","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00018-023-04729-4","article-title":"Receptor tyrosine kinase inhibitors in cancer","volume":"80","author":"Ebrahimi","year":"2023","journal-title":"Cell Mol Life Sci"}],"container-title":["Medicine in Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590098624000204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590098624000204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:21:10Z","timestamp":1728260470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590098624000204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":100,"alternative-id":["S2590098624000204"],"URL":"https:\/\/doi.org\/10.1016\/j.medidd.2024.100195","relation":{},"ISSN":["2590-0986"],"issn-type":[{"value":"2590-0986","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Medicine in Drug Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medidd.2024.100195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100195"}}